IRON

Disc Medicine, Inc. (IRON) | Rumor.io

Disc Medicine

IRON

Attention (50-day avg)0%

Attention rank (50-day avg)#2,204

Bullish sentiment (50-day avg)0%

Price to earnings ratio4.99

Market capitalization2.5B

Earnings per share-6.59

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-212.2M

Social

What share of all stock conversation is about IRON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 7

The FDA's vaccine division head has stepped down, potentially leading to changes in the regulatory environment.
This shift may impact biotech companies, with Disc Medicine, Inc. (IRON) being a potential beneficiary.
The change in leadership may also affect mRNA vaccine makers, with Moderna (MRNA) being a focus of attention.

Generated by AI

Sentiment

Of the messages about IRON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.93% -9.65
Bearish	—	—	—	21.07% +9.65

Bullish· Apr 1

Disc Medicine, Inc. (IRON) has been identified as a buy opportunity due to its potential to resolve placebo issues, making it an "unbelievable buy opportunity".
The company's cash runway until 2026, combined with analysts reiterating a buy rating and a $70 price target, makes it a strong candidate for a big bounce.
IRON's price has shown significant growth, with some investors making profits of over 10% in a short period of time, and analysts maintaining a price target of $75.

Bearish· Apr 1

$IRON's price drop is likely due to the company's announcement of a failed phase 2 trial, which was not adequately flagged by analysts.
The company's high burn rate and limited cash reserves increase the risk of further price declines, potentially leading to a worst-case scenario of around $10 per share.
The recent price drop of $IRON is a sign of the market's overvaluation, with the stock experiencing a 55% decline after a minor setback, highlighting the risks of investing in an overpriced market.

Generated by AI

Topics

Of the messages about IRON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	75.27%
Analysts	—	—	0%	2.18%
Controversies	—	—	0%	4.67%
Earnings	—	—	0%	0.62%
Macro	—	—	0%	1.09%
Technical Analysis	—	—	0%	16.17%

Oct 17

Disc Medicine's ($IRON) bitopertin, a rare-disease therapy, received an FDA Commissioner's National Priority Voucher for treating erythropoietic protoporphyria (EPP), potentially accelerating approval.
The voucher could cut FDA review time to 1-2 months, and Wedbush maintained an Outperform rating on $IRON after the announcement.
Disc Medicine will present data from a Phase 1b trial of DISC-0974 in patients with chronic kidney disease (CKD) and anemia at the 2025 American Society of Nephrology (ASN) Kidney Week, with $IRON shares trading higher as a result.

Generated by AI

Community

Of the messages about IRON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	43.11%	35.15%
Newcomers	100%	100%	56.89%	64.85%

Mar 7

Newcomers are focused on the potential impact of the FDA's changing regulatory environment on the biotech sector, with Iron (IRON) being a key player in this shift.
Some users are drawing attention to Iron (IRON) as a company that could benefit from a sector rotation, given its focus on bio-medicines.
The departure of the FDA's vaccine division head is seen as a signal for change, with some users mentioning mRNA (MRNA) as a company that may need to adapt to this new regulatory landscape, but others are focusing on Iron (IRON) as a key player in the bio-medicines sector.

Generated by AI

News

Disc Medicine at Morgan Stanley conference: pipeline nears key tests

15d agoInvesting.com

Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones

19d agoBenzinga

Also Discussed

Investors talking about IRON also mention

#	Name	Attention
1	Spruce Biosciences, Inc.SPRB	0%0
2	ARMN - Aris Mining Corporation	——
3	SNPO - Snap One Holdings Corp.	——
4	PC Connection, Inc.CNXN	0%0
5	Solidion Technology Inc.STI	0%new
6	CytomX Therapeutics, Inc.CTMX	0%0
7	MiMedx Group, Inc.MDXG	0%0
8	United Community Banks, Inc.UCBI	0%new
9	International Bancshares Corp.IBOC	0%0
10	CSGS - CSG Systems International, Inc.	——

Disc Medicine, Inc.

Healthcare
Biotechnology

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s work centers on red blood cell biology, with programs designed to address disorders involving heme biosynthesis and iron homeostasis. Its current pipeline includes therapies in development for rare blood diseases such as erythropoietic porphyrias, Diamond-Blackfan anemia, anemia associated with myelofibrosis, and polycythemia vera. Disc Medicine operates as a research-driven biotech business, advancing both clinical and preclinical candidates aimed at modifying fundamental biological pathways rather than offering broad commercial products. Headquartered in Watertown, Massachusetts, Disc Medicine plays a specialized role in the hematology market by concentrating on diseases with significant unmet medical need and limited treatment options.

Website

Location

321 Arsenal Street

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about IRON?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Mar 7

The FDA's vaccine division head has stepped down, potentially leading to changes in the regulatory environment.
This shift may impact biotech companies, with Disc Medicine, Inc. (IRON) being a potential beneficiary.
The change in leadership may also affect mRNA vaccine makers, with Moderna (MRNA) being a focus of attention.

Generated by AI

Sentiment

Of the messages about IRON that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.93% -9.65
Bearish	—	—	—	21.07% +9.65

Bullish· Apr 1

Disc Medicine, Inc. (IRON) has been identified as a buy opportunity due to its potential to resolve placebo issues, making it an "unbelievable buy opportunity".
The company's cash runway until 2026, combined with analysts reiterating a buy rating and a $70 price target, makes it a strong candidate for a big bounce.
IRON's price has shown significant growth, with some investors making profits of over 10% in a short period of time, and analysts maintaining a price target of $75.

Bearish· Apr 1

$IRON's price drop is likely due to the company's announcement of a failed phase 2 trial, which was not adequately flagged by analysts.
The company's high burn rate and limited cash reserves increase the risk of further price declines, potentially leading to a worst-case scenario of around $10 per share.
The recent price drop of $IRON is a sign of the market's overvaluation, with the stock experiencing a 55% decline after a minor setback, highlighting the risks of investing in an overpriced market.

Generated by AI

Topics

Of the messages about IRON that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	75.27%
Analysts	—	—	0%	2.18%
Controversies	—	—	0%	4.67%
Earnings	—	—	0%	0.62%
Macro	—	—	0%	1.09%
Technical Analysis	—	—	0%	16.17%

Oct 17

Disc Medicine's ($IRON) bitopertin, a rare-disease therapy, received an FDA Commissioner's National Priority Voucher for treating erythropoietic protoporphyria (EPP), potentially accelerating approval.
The voucher could cut FDA review time to 1-2 months, and Wedbush maintained an Outperform rating on $IRON after the announcement.
Disc Medicine will present data from a Phase 1b trial of DISC-0974 in patients with chronic kidney disease (CKD) and anemia at the 2025 American Society of Nephrology (ASN) Kidney Week, with $IRON shares trading higher as a result.

Generated by AI

Community

Of the messages about IRON, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	43.11%	35.15%
Newcomers	100%	100%	56.89%	64.85%

Mar 7

Newcomers are focused on the potential impact of the FDA's changing regulatory environment on the biotech sector, with Iron (IRON) being a key player in this shift.
Some users are drawing attention to Iron (IRON) as a company that could benefit from a sector rotation, given its focus on bio-medicines.
The departure of the FDA's vaccine division head is seen as a signal for change, with some users mentioning mRNA (MRNA) as a company that may need to adapt to this new regulatory landscape, but others are focusing on Iron (IRON) as a key player in the bio-medicines sector.

Generated by AI

Disc Medicine

Social

Mar 7

Bullish· Apr 1

Bearish· Apr 1

Oct 17

Mar 7

Disc Medicine at Morgan Stanley conference: pipeline nears key tests

Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones

Disc Medicine at Wells Fargo conference: two drug bets near key tests

H.C. Wainwright reiterates Disc Medicine stock rating on trial data

Disc Medicine stock rating held at Outperform by BMO on trial data

Jefferies reiterates Disc Medicine stock rating on polycythemia data

Also Discussed

Disc Medicine, Inc.

Company Information

Location

Disc Medicine at Morgan Stanley conference: pipeline nears key tests

Disc Medicine Shares Polycythemia Vera Data, Outlines Late 2026 Trial Milestones

Disc Medicine at Wells Fargo conference: two drug bets near key tests

H.C. Wainwright reiterates Disc Medicine stock rating on trial data

Disc Medicine stock rating held at Outperform by BMO on trial data

Jefferies reiterates Disc Medicine stock rating on polycythemia data

Also Discussed

Social

Mar 7

Bullish· Apr 1

Bearish· Apr 1

Oct 17

Mar 7